PIK3CA mutation detection in metastatic biliary cancer using cell-free DNA
Metrics: PDF 1042 views | HTML 1508 views | ?
Seung Tae Kim1,*, Maruja Lira2,*, Shibing Deng2, Sujin Lee1, Young Suk Park1, Ho Yeong Lim1, Won Ki Kang1, Mao Mao3, Jin Seok Heo4, Wooil Kwon4, Kee‑Taek Jang5, Jeeyun Lee1,6, Joon Oh Park1,6
1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2Precision Medicine, Oncology Research Unit, Pfizer, Inc, San Diego, CA, USA
3WuXi AppTec, Shanghai, China
4Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
5Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
6Innovative Cancer Medicine Institute, Samsung Medical Center, Seoul, Korea
*These authors have contributed equally to this work
Joon Oh Park, e-mail: firstname.lastname@example.org
Jeeyun Lee, e-mail: email@example.com
Keywords: cell free DNA (cfDNA), PIK3CA mutation, droplet digital PCR (ddPCR)
Received: July 13, 2015 Accepted: October 05, 2015 Published: October 16, 2015
PIK3CA mutation is considered a good candidate for targeted therapies in cancers, especially biliary tract cancer (BTC). We evaluated the utility of cell free DNA (cfDNA) from serum by using droplet digital PCR (ddPCR) as an alternative source for PIK3CA mutation analysis. To identify matching archival tumour specimens from serum samples of advanced BTC patients, mutation detection using ddPCR with Bio-Rad’s PrimePCR mutation and wild type assays were performed for PIK3CA p.E542K, p.E545K, and p.H1047R. Thirty-eight patients with metastatic BTC were enrolled. Only one (BTC 29T) sample (n = 38) was positive for PIK3CA p.E542K and another (BTC 27T) for p.H1047R mutation; none was positive for PIK3CA p.E545K. Matched serum sample (BTC 29P) was positive for PIK3CA p.E542K with 28 mutant copies detected, corresponding to 48 copies/ml of serum and an allelic prevalence of 0.3%. Another matched serum sample (BTC 27P) was positive for PIK3CA p.H1047R with 10 mutant copies detected, i.e. 18 copies/ml and an allelic frequency of 0.2%. High correlation was noted in the PIK3CA mutation status between tumour gDNA and serum cfDNA. Low-level PIK3CA mutations were detectable in the serum indicating the utility of cfDNA as a DNA source to detect cancer-derived mutations in metastatic biliary cancers.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.